Target intelligence / Profile preview

Kinesin family member 24 (KIF24)

Target
KIF24
Molecular classification
Kinesin superfamily, Microtubule-based motor protein, Sterile alpha motif (SAM) domain containing protein, Motor protein
01

Overview

Kinesin family member 24 (KIF24) is a microtubule-based motor protein in the kinesin-13 subfamily that localizes to the mother centriole and acts as a negative regulator of ciliogenesis by depolymerizing centriolar microtubules and restricting aberrant cilia formation[1][4]. KIF24 interacts with centrosomal proteins (notably CP110 and Cep97) and is essential for the dynamic assembly and disassembly of primary cilia, a process critical for proper cell cycle progression and signaling. NEK2-mediated phosphorylation activates KIF24 during the S/G2 phases, promoting cilium disassembly and preventing cilia regrowth in dividing cells, a mechanism implicated in the control of cell proliferation and, when dysregulated, in certain cancers[1][3][4]. Disease relevance is supported by genetic evidence linking KIF24 variants to frontotemporal lobar degeneration and skeletal dysplasias, manifesting features of ciliopathies and providing insight into the biological importance of centriolar and ciliary dynamics[1][4]. No drugs have been reported to target KIF24 directly.

Other names
Kinesin-like protein KIF24C9orf48bA571F15.4FLJ10933FLJ43884
02

Mechanism of action

Not applicable (no known drugs)

03

Biological functions

Microtubule depolymerizationNegative regulation of ciliogenesis (assembly and disassembly of cilia)Intracellular transport (membranous organelles, protein complexes, mRNA)Cell cycle progression (notably via cilium disassembly in S/G2 phase)MorphogenesisRecruitment of centrosomal proteins (e.g., CP110, Cep97)
04

Disease associations

Cancer (due to dysregulation potentially enhancing cell proliferation and transformation)Neurodegenerative disease (polymorphisms associated with risk of frontotemporal lobar degeneration)Skeletal disorders/skeletal ciliopathies (biallelic missense variants leading to disorders from mild skeletal abnormalities to prenatally lethal forms)
05

Safety considerations

Not established—no direct targeting, but mutations impact cilia function and skeletal/neural pathology

Beyond the preview

Go deeper on Kinesin family member 24 (KIF24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinesin family member 24 (KIF24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call